Liquidia falls after United Therapeutics files new patent suit over inhaled drug

Shares of biopharma firm Liquidia Corp LQDA.O fall 5% to $14.50 premarket

United Therapeutics Corporation UTHR.O filed a litigation against Liquidia on May 9 in the U.S. District Court of North Carolina, alleging infringement of U.S. Patent, LQDA says

The lawsuit seeks to block Liquidia from launching its inhaled drug, Yutrepia, if approved by the FDA

Liquidia has faced multiple delays to bringing Yutrepia to the U.S. market

The drug was granted tentative approval in 2021 to treat pulmonary arterial hypertension (PAH), but Liquidia could not market it due to a regulatory stay related to a patent infringement dispute with United

Company says the new lawsuit does not affect the FDA's ability to make a final decision on Yutrepia by May 24

As of last close, LQDA was up ~30%